132646-31-2

Upstream product

• 103788-62-1 4-bromoacetyl-5-methyl-2-phenyl-oxazole 
• 1761-61-1 5-bromosalicyclaldehyde 

Downstream Products

• 132672-20-9 5-bromo-α-(5-methyl-2-phenyloxazol-4-yl)-2-benzofuranmethanol 
• 132646-45-8 5-(2-(5-methyl-2-phenyloxazol-4-ylmethyl)-benzofuran-5-ylmethyl)-oxazolidine-2,4-dione 
• 132646-43-6 5-<2-<<(5-methyl-2-phenyl-4-oxazolyl)methyl>-5-benzofuranyl>methylidene>-2-thio-2,4-oxazolidinedione 
• 132646-44-7 5-<2-<<(5-methyl-2-phenyl-4-oxazolyl)methyl>-5-benzofuranyl>methylidene>-2,4-oxazolidinedione 
• 1026734-02-0 N-[2-(5-methyl-2-phenyl-oxazol-4-ylmethyl)-benzofuran-5-ylmethyl]-hydroxylamine 
• 174258-63-0 1-[2-(5-methyl-2-phenyloxazol-4-ylmethyl)benzofuran-5-yl]ethanone 
• 174258-62-9 1-[2-(5-methyl-2-phenyloxazol-4-ylmethyl)benzofuran-5-yl]ethanol 
• 132646-33-4 2-<(5-methyl-2-phenyl-4-oxazolyl)methyl>benzofuran-5-carbonitrile 
• 132646-34-5 2-(5-methyl-2-phenyl-4-oxazolyl)methyl-5-benzofurancarboxaldehyde 
• 132646-32-3 2-[(2-Phenyl-5-methyloxazol-4-yl)methyl]-5-bromobenzofuran 

Relevant academic research and scientific papers

Antihyperglycemic activity of new 1,2,4-oxadiazolidine-3,5-diones

A series of 1,2,4-oxadiazolidine-3,5-diones was synthesized and evaluated as oral antihyperglycemic agents in the obese insulin resistant db/db and ob/ob mouse - the two models for Type 2 diabetes mellitus. The majority of the prepared methoxy- and ethoxy-linked oxazole 1,2,4-oxadiazolidine-3,5-diones normalized plasma glucose levels at the 100 mg kg-1 oral dose in the db/db diabetic mouse model, and several amongst them reduced the glucose levels at the 20 mg kg-1 oral dose. The most potent compounds in the db/db mouse model were also active in the ob/ob mouse model normalizing the plasma glucose levels at the 20 mg kg-1 oral dose. The trifluoromethoxy analog 32 was the most active compound of the series, reducing significantly the plasma glucose levels at the 5 mg kg-1 oral dose. Oxadiazole-tailed 1,2,4-oxadiazolidine-3,5-diones were also active in both the db/db and ob/ob diabetic mouse models normalizing plasma glucose levels at the 100 mg kg-1 oral dose.

Hypoglycemic hydroxyurea derivatives

There are disclosed preparative processes and hypoglycemic compounds of the formula STR1 wherein R is hydrogen or C1 to C3 alkyl; R1 and R2 are taken together and are carbonyl; or R1 and R2 are taken separately, wherein R1 is hydrogen or R4 and R2 is--COR5 and COOR5 ; R3, R4 and R5 are each independently C1 to C9 alkyl, C3 to C7 cycloalkyl, phenyl, naphthyl, furyl, benzofuryl or thienyl or one of said groups mono- or disubstituted with C1 to C3 alkyl, C1 to C3 alkoxy, C1 to C3 alkoxy-carbonyl, trifluoromethyl, fluoro or chloro; and n is 0 or 1; or pharmaceutically acceptable cationic salts thereof.

Benzyloxazolidine-2,4-diones as potent hypoglycemic agents

A series of benzyloxazolidine-2,4-diones, containing oxazole-based side chains, were found to lower blood glucose levels in the genetically obese ob/ob mouse. Incorporation of a benzofuran structural element in these compounds provides greatly enhanced in vivo potency. The syntheses and structure-activity relationships for this series are detailed.